12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Civacir: Phase III started

Biotest began the open-label, North American Phase III Study 988 to evaluate 200 and 300 mg/kg Civacir in up to 90 patients. Patients will receive Civacir starting on the day of liver transplant, but prior to the transplant, followed by 15 infusions over 10...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >